The Role of S100A6 in Pancreatic Cancer Development and Its Clinical Implication as a Diagnostic Marker and Therapeutic Target

• DOI: 10.1158/1078-0432.ccr-05-0714
• Publication Date: 2006-03-21T18:43:43Z
• Authors: Kenoki Ohuchida; Kazuhiro Mizumoto; Nami Ishikawa; Kei Fujii; Hiroyuki Konomi; Eishi Nagai; Koji Yamaguchi; Masazumi Tsuneyoshi; Masao Tanaka
• Keywords: Microdissection; Tissue microarray; Pancreatic Disease; Pancreatic Intraepithelial Neoplasia; CA19-9

Abstract Recent microarray analyses showed that the S100 family contains members are candidate diagnostic markers or therapeutic targets. In present study, to evaluate involvement of S100A6 in pancreatic cancer and its clinical usefulness for diagnosis, we examined mRNA expression tissues juice from patients with different diseases. To investigate role carcinogenesis potential as a marker early detection cancer, did immunohistochemistry microdissection-based analysis normal ducts, intraepithelial neoplasias, invasive ductal carcinomas. We also used vitro experiments RNA interference functional target cancer. levels were significantly higher carcinoma specimens than nonneoplastic tissues. juice, there was significant difference between those disease. Receiver operating characteristic curves revealed might be useful diagnosis Immunohistochemistry differential among data inhibition decreased proliferation invasiveness cells, these findings supported by data. Our results suggest quantitation is promising tool may